This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Dumbest Things on Wall Street This Week: April 5

5. Repros Reproach

Markets were closed last Friday in honor of Good Friday. Luckily for us, Repros Therapeutics (RPRX) CEO Joe Podolski generously provided more than enough dumbness last Thursday to tide us through the long holiday weekend.

On a conference call last Thursday morning, Podolski told analysts that his experimental testosterone drug Androxal helped gay Cubans have more sex. The gay Cubans entered the clinical trial with low testosterone, according to Podolski, yet after taking Androxal, their testosterone levels soared, leading to lots and lots and lots of sex.

Seriously, we're not joking. We may kid about a lot of things, but gay Cuban sex is not one of them.

Anyway, Podolski said the gay Cuban men had so much sex that it caused their sperm counts to drop precipitously. But he urged the crowd not to blame the plunge on Androxal. Podolski maintained instead that the lower sperm counts were the result of the gay Cubans having so much sex that their ammunition ran low.

What more can we say Dumbest fans? Res ipsa loquitur .

And if that wasn't enough, TheStreet's Adam Feuerstein reported that at another point during the conference call, Podolski disclosed that a nurse at one of the Androxal clinical trial sites fabricated baseline sperm counts for patients. When Repros discovered the data fraud, the company changed the fishy numbers and everything turned out fine.

A second phase III study of Androxal is under way with enrollment expect to wrap in May. Podolski insisted the data announced Thursday should convince investors that the second study will also be positive.

Repros bulls are probably looking forward to the next report and not just for its racy content. Shares of the stock spiked nearly 80% on Podolski's pronouncements despite the trial's inconsistencies and the missing Androxal data.

Then again, fundamentals aren't really a factor when it comes to Repros stock. Nearly half the company's shares have been sold short, opening up the possibility for the bulls to once again squeeze the bears where it hurts.

And that can't be good for their sperm counts either.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FBN $0.00 0.00%
DELL $0.00 0.00%
AAPL $92.69 -0.59%
RPRX $2.10 -3.40%
FB $119.49 1.43%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs